OP14 Cost-Utility Analysis Of Regorafenib For Patients With Hepatocellular Carcinoma Who Progressed On Sorafenib Treatment
- Ambrish Singh
- , Salman Hussain
No endorsements
This article has not been endorsed yet.
Like this work?
Let others know. Sign in to add your endorsement.